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ABSTRACT
The work is devoted to the application and further development of modern statistical 
methods to study pharmacokinetics of drugs. Specifically, it deals with applications 
and development of repeated measures analysis, so called 'population approach' 
methods, in the field of pharmacokinetics. hi the first part of the thesis, a new, model- 
free approach is developed and tested. It introduces a model-free measure of patient's 
exposure to drugs, and then investigates the relationships between the exposure level 
and covariates using various statistical techniques. Classification tree models (CART) 
and regression analysis are used to study various subpopulations of interest. It is 
shown, via simulations, that the model-free method is capable to identify predictors of 
exposure in a wide range of variability in the data. The non-linear mixed effect 
modelling is used to confirm the results of the model-free investigation. Model-free 
approach is successfully applied to several drugs. Non-linear Mixed Effects 
population models developed for the same data agree with its results. Limits of the 
new method are also identified. Specifically, it does not allow the estimation of the 
variability: either the within-subject (intra-individual) variability in response, or 
between-subject (inter-individual) variability of the pharmacokinetic parameters in the 
population. The second part of the thesis is devoted to applications of the Non-linear 
Mixed Effect methodology to population pharmacokinetics and dose-response 
analysis. Population pharmacokinetic and dose-response models of several drugs are 
developed. Pharmacokinetic models allow for complete characterisation of the drug's 
pharmacokinetics and its relationships to safety and efficacy. The developed models 
are used to explore the relationships between the exposure (individual Bayes 
estimates) and demographic predictors of exposure, and safety and efficacy of the 
drug. Finally, the developed models are used in simulations to guide the design of new 
studies
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1 INTRODUCTION
The work is devoted to application and further development of modern statistical 
methods to study pharmacokinetics of drugs. Due to the dual (statistical and 
biological) nature of the work, it requires some introduction to the field and definition 
of pharmacokinetic terms. Let us begin with such an introduction.
1.1 Overview Of Principles Of Pharmacokinetics
When a drug is given (administered) orally to a human or an animal, it first enters the 
systemic circulation (a blood stream) through complex absorption mechanisms 
[Rowland & Tozer, 1995]. Following absorption, it is distributed to different tissues 
in the body. On passage through organs of elimination (e.g., liver, kidneys, etc.) it is 
eliminated (cleared) from the body. The amount of drug in each tissue is not constant. 
It rises following administration of the drug, then decreases, and eventually is cleared 
completely. Figure 1 depicts the typical pharmacokinetics or time course of the drug 
(i.e., time dependence of the amount of the drug in an organ) in different tissues 
following a single oral dose of a drug.
Is-
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Blood plasma
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Time, t
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Figure 1. Typical drug pharmacokinetics after a single oral dose.
Pharmacological action of a drug, positive (efficacy) or negative (toxicity) depends on 
the amount of the drug at the site of action. Therefore, for optimal therapy (therapy 
that balances desired and side effects of the drug) understanding of the kinetics of the 
drug is crucial. However, most internal organs in humans are difficult to access, and 
the amount of the drug in the tissue can not be measured directly. Instead one typically
16
measures the drug concentration in blood or blood plasma (also in urine, feces, milk, 
etc). From this profile (a time course) one can characterise pharmacokinetics of the 
drug in the body. The field of science that study the time course of absorption, 
distribution and elimination of drugs in the body is called pharmacokinetics (PK) 
[Gibaldi & Perrier, 1982].
Several pharmacokinetic parameters are commonly used to characterise drug 
pharmacokinetics. The most important are:
  Area under the concentration versus time curve (AUC);
  Maximal achieved concentration (Cmax);
  Time to achieve the maximal concentration (tmax);
  Clearance (Cl), defined as the proportionality coefficient between the rate of drug 
elimination from the body and the drug concentration in plasma. Clearance 
represents the volume of plasma that is cleared of drug per unit of time;
  Apparent volume of distribution (V), defined as a proportionality coefficient 
between the amount of drug in the body and drug concentration in plasma;
  Bioavailability (F), defined as fraction of the dose absorbed into systemic 
circulation;
  Half-life (t\/2) that is the time that takes to lower plasma concentration of the drug 
in half.
Repeated administration of a drug eventually (after several doses) yields steady-state 
concentrations of the drug in different tissues. These concentrations typically 
fluctuate periodically, with the period of dosing. The pharmacokinetic parameters at 
steady state may differ from those following a single dose. The relationship between 
single and multiple-dose pharmacokinetics is an important feature of the drug kinetics.
1.2 Compartmental Methods
Mathematical models that describe pharmacokinetics may be purely empirical or may 
have a physiological meaning. The most widely used pharmacokinetic models are the 
so-called compartmental models. They assume that the body consists of several 
'compartments' storing the drug, as shown schematically in Figure 2. The drug
17
transfers between the compartments and is eliminated following some functional 
relationships. The central compartment 1 may, for example, represent blood that 
transfers the drug to all the other tissues, presented by peripheral compartments 2 and 
3.
21 I
2 -* 1 -» 3
T
Figure 2. Three-compartment model with input into and elimination from the 
central compartment.
The compartment models aim to describe the disposition of the drug (e.g., 
concentration time course of the drug) in any compartment given concentration 
measurements from an individual at known times and the history of dosing. They can 
be described by systems of ordinary differential equations of the form;
at < (0 -
= Eq. 1
7*'
where X\ represents the amount of the drug in the i-th compartment, Ij (t) is an input 
function into the i-th compartment from outside the system, ky- and kj,ei are the rates of 
transfer between the compartments and rates of loss of drug, respectively, and n is the 
number of compartments in the model.
Usually, the transfer and the elimination rates, ky- and kj ei, are assumed to be constant. 
Then the system is linear, and the solution is described by a sum of several 
exponential terms. Combinations of the rate constants then describe all the 
pharmacokinetic parameters of the drug.
The scope of compartmental modelling is to define functional relationships between 
the compartments and to estimate the parameters that describe the data. Estimation of 
unknown parameters of compartmental models is usually performed with the 
nonlinear regression.
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1.3 Variability In Pharmacokinetics
Different people respond differently to the same drug, and the same individual may 
have different responses (drug concentrations) on different occasions. Many factors 
can contribute to the inter-individual (between subjects) and intra-individual (within a 
subject) variability. Factors such as genetics, diseases, age, weight, and gender 
contribute to inter-individual variability, while drugs given concomitantly, 
environmental factors, non-compliance, food, time of the day and season can 
contribute to intra-individual variability. Determining subpopulations with altered 
kinetics has the implication for the choice of an appropriate dosing regimen (that is, 
the way of administering the drug, such as once or twice a day, orally or 
intravenously, etc.).
1.4 Two-Stage Approach
The traditional way to deal with variability is to use the two-stage method. First, the 
kinetics is described individually for a number of subjects from a homogeneous 
population (holding all factors contributing to variability constant), and 
pharmacokinetic parameters are derived for each subject. Then the population values 
of each parameter (mean and variance or coefficient of variation) are computed from 
the empirical distribution of individual estimates of the parameter. To define the 
influence of a specific factor on the drug kinetics, several populations that differ only 
in that factor should be compared with respect to their parameters (e.g., young versus 
elderly, fed versus fasted, etc.) [Rowland & Tozer, 1995].
This approach is widely used in pharmacokinetic studies, and until recently it has been 
the only method used. However, it has many limitations as discussed by Beal and 
Sheiner [1985], and Sheiner [1984].
Firstly, the two-stage method can be applied only to small pharmacokinetic studies 
under restrictive inclusion criteria. These studies are usually short and well controlled. 
They employ few dosing regimens and small number of usually healthy subjects who 
do not take other drugs. Many measurements are taken from each person allowing the 
description of the kinetics in each individual. To have enough power for comparisons,
19
these studies are designed to compare kinetics with respect to only few factors. Thus, 
they cannot be used to study several correlated influential factors.
Secondly, in order to distinguish between inter- and intra-individual variability, 
traditional studies have to employ artificial and complex designs. These designs are 
not representative of clinical practice and usually can not be carried out in studies that 
involve real patients.
1.5 Population Approach
In patient studies (population studies), where the primary objective is the investigation 
of the drug safety and efficacy, the optimal pharmacokinetic designs are neither 
feasible nor desirable. Design of patient studies is dictated by the therapeutic goals. 
From the pharmacokinetic prospective these studies have non-experimental 
(observational) design. Only a few measurements are usually available per individual. 
The timing and number of measurements may differ between subjects, dosing 
regimens may also differ. This type of data is called sparse data. The population 
included in such studies is much broader and less homogeneous. Many factors can 
contribute to pharmacokinetic variability of a particular drug in a patient population. 
The number of homogeneous subpopulations can also be very large (and unknown a 
priori). The two-stage approach is not appropriate in dealing with such data.
A more recent approach for analysing sparse kinetic data from a population (called 
population approach) was first proposed by Sheiner et al. [1972]. Its first published 
application was five years later [Sheiner & Rosenberg, 1977] and the first software for 
analysing data in this manner, NONMEM, was released in 1980 [Beal & Sheiner, 
1980]. Since then, the population approach has been an area of active research [Beal, 
1998; Grasela & Sheiner, 1991; Sheiner & Grasela, 1991]. The approach uses the 
Nonlinear Mixed Effects regression Model to analyse the data pooled over all 
individuals (see an overview by Sheiner & Ludden [1992]).
The population model combines a pharmacokinetic model, called the structural 
model (for example, a compartmental model) and a statistical model. The basic idea 
behind the population model is that the same mathematical equation describes the 
response for any particular individual, but the underlying structural parameters of this
20
equation vary from individual to individual. The overall variability in the measured 
response reflects the inter-subject variability in kinetics and the residual variation. The 
latter includes the intra -individual variability and a measurement error.
Individual structural (pharmacokinetic) parameters are modelled in terms of fixed and 
random effects. Fixed effects account for inter-individual differences in the values of 
individual covariates (age, sex, liver function, severity of a disease or other 
demographic or laboratory data). Random effects of the first type account for 
unexplained inter-individual variability in the pharmacokinetic parameters. Random 
effects of the second type account for residual variability. The full set of assumptions 
and models on (i) pharmacokinetic structural relationships, (ii) inter-individual 
variation and (iii) residual error variance build a "pharmacostatistical" population 
model.
A form of the Nonlinear Mixed-Effect Model sufficiently general for our purposes is 
given by the equation:
yy = fjj(Dik, tD ik , ty; (£) + 6ij(D ik, tD ik, ty; (&), Eq. 2
where the index i=!,...,! denotes the subject (I is the number of subjects), the index 
j=l...,Ji denotes an observation (Jj is the number of observations for the subject i), and 
k=l,.. .,Kj denotes a dose administration (Kj is the number of doses administered to 
the subject i). The observed plasma concentration yy (or it's transformed value, such 
as log concentration) is a noise-corrupted realisation of the expected value for the j-th 
observation on the i-th subject. This model assumes the existence of some parametric 
function of time fy(D ik, tD ik, ty; (£j) (a structural model) that describes the expected 
response (e.g., plasma concentration) in a subject. The vectors Dik and tD ik describe 
the dosing history of an ith subject, and the vector ty describes times of the 
observations. The vector (& is the vector of pharmacokinetic parameters for the ith 
subject. The random noise ey that perturbs the expected value of yy is represented in 
(Eq. 2) as a function to indicate that its distribution (e.g., variance) may depend on 
dose, time and pharmacokinetic parameters.
The vector of parameters <j>j vary randomly among the subjects. It is a function
21
<fc = h(xi; 0, r,,) Eq. 3
of the vector of parameters 0 (the fixed effects that characterise the population), on the 
collection x; of covariates, and on the vector of random effects T^ The random effects 
Hi and 8y are assumed to have zero expectations
E(aO = 0, E(Eij ) = 0, Eq. 4 
and be statistically independent
Cov(Hi, 8ij) =0 . Eq. 5
The variance-covariance matrix of inter-individual random effects and variance of 
intra-individual random effects are denoted as Q and a2 , respectively, i.e.,
Var(8ij)=a2 , i=l,.-,I; j=l,-..,Ji   Eq. 6
(In a more general model, e^ may be a vector; its variance-covariance matrix is then 
denoted as £).
Thus, the pharmacokinetics of the drug is completely described within the given 
model by (i) vector of the population parameters 0, (ii) vectors of individual random
*\
effects rji (or its variance-covariance Q), and (iii) variance of residuals a (or the 
variance-covariance matrix S).
The simplest method for estimation of unknown parameters is the so-called First - 
Order method [Sheiner, et al, 1972]. It approximates the nonlinear model with a 
model that is linear in all random effects by using a first-order Taylor expansion in all 
random effects around zero [Beal, 1984]. To illustrate the method let us rewrite (Eq. 
2) and (Eq. 3) in a more general form:
Eq. 7
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including into Xy the covariates Xj, the dosage histories Dik, to ik, and the sampling 
time histories tjj. Then the first-order model can be written as
ytj = ,,, + --,,q , +-,,,, -. Eq . 8
The estimates of the model parameters 0, Q and I are then obtained by the extended 
least squares method [Real, 1984]. Under the assumption of normality of random 
effects, the extended least squares yields maximum likelihood estimates for the first - 
order model [Beal, 1984].
The first -order method produces estimates of the population parameters 0, Q and L, 
but it does not obtain estimates of the random inter-individual effects r^. An estimate 
of Hi, conditional on the first order estimates for 0 and Q (at zero value of I) can be 
obtained by maximising the empirical Bayes posterior density of TJJ, given the vector 
yij for the ith individual [Beal & Sheiner, 1998]. Since the estimate 3.1 is obtained after 
the population estimates, it is called theposthoc estimate.
The first-order method was implemented in the software NONMEM, and is referred to 
as FO method.
In contrast to the first-order method, conditional estimation methods (also 
implemented in NONMEM [Beal & Sheiner, 1998]) produce estimates of the 
population parameters 0, Q and L and, simultaneously, estimates of the random inter- 
individual effects T|J. They maximise the likelihood for all the data with respect to 0, 
L, H and Tjj. Different methods use different approximations to the likelihood. These 
methods are very time-consuming and prone to problems. Therefore, they are used 
only when the FO method produces biased estimates.
The NONMEM software that implements FO and conditional estimation methods has 
become a standard for nonlinear mixed effect modelling in the pharmaceutical 
industry. The alternatives include other Gaussian maximum likelihood algorithms 
based on different linearisations of the model [Lindstrom & Bates, 1990; Vonesh, 
1992; Vonesh & Carter, 1992; Wolfinger, 1993], semi-nonparametric maximum
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according to observed interim response, are used more and more often. The mixed- 
effects methodology is the only option for deriving dose-response relationships in 
such studies.
1.6 Model-Free Approach
Nonlinear mixed-effects modelling is a very powerful technique. However, it has its 
own limitations. Firstly, it is a very time intensive method [Steimer, et al, 1994]. 
Secondly, it requires an answer to the following question: how do the structural and 
covariate models, f\j and h, depend on their arguments? Seldom, if ever, does theory 
provide a priori answers to these questions. Exploratory diagnostic techniques have 
been developed to guide the selection of model form fy and covariate dependencies h 
[Ette & Ludden, 1995; Mandema, et al, 1992]. The success of these exploratory 
methods led to the idea of using nonparametric "exploratory" data analysis methods 
developed by Chambers et al. [1983]. Such an analysis is especially useful when the 
data has a fairly simple structure, e.g., in the situation of steady state dosing with the 
same dose given to all the individuals. These nonparametric exploratory methods are 
essentially a mix of graphical and statistical techniques (see [Pollak, 1990] for a 
general survey of exploratory methods).
Motivated by Ebelin et al. [1992 ] and Laplanche et al. [1991], where exploratory 
analysis were made primal, a nonparametric, model-free, approach to pharmacokinetic 
population analysis has been developed [Gibiansky, et al, 1997, 1999; Nedelman, et 
al, 1995,1996]. The basic idea of the model-free approach is to categorise patients 
into groups according to their exposure, using graphical algorithms, and then use 
various statistical techniques to explore association of these groups with the 
covariates.
The approach involves partitioning observed plasma concentrations into several 
regions (observation levels) taking into account time of concentration measurements. 
Patients are then partitioned into 'exposure levels' depending on which observation 
level their concentrations fall into. Exposure level serves as a new response - an 
ordered factor that characterises the exposure to the drug. It can be explored for an 
association with covariates. Depending on the goals of the investigation a variety of 
statistical techniques can be used: from univariate measures of association to elaborate
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multivariate classification and regression tree (CART) analysis [Breiman, et al., 
1984]. Quantitative measures of exposure, individual (Area Under Quartile or AUQ) 
and population (Area Under Population Curve or AUPC) can also be derived. This 
allows for comparisons of exposure for subpopulations. Both, the exposure level and 
the individual AUQ, can also be used as a covariate in pharmacodynamic models, 
models that relate drug effect to pharmacokinetic parameters.
The method has been evolving over time. First, it was mostly a qualitative method, 
designed to serve as a screening tool for parametric modelling, the aim was to reduce 
the number of variables in the model building process. It later developed into an 
elaborate statistical technique able to stand on its own.
In the present work the aforementioned techniques are developed and applied to 
several drugs under development. The structure of the work is the following.
1.7 Organisation of the thesis
Chapter 2 starts with a simpler, model-free approach. It describes the evolution of the 
approach as it is applied to three projects, three different drugs. In the first two 
sections (Sections 2.1 and 2.2), model-free approach served as a screening tool: results 
were to be incorporated into model building of the nonlinear mixed-effects model 
[Nedelman et al., 1995, 1996]. Therefore, the most interest was in qualitative results. 
In the third section (Section 2.3) the model-free approach was meant to be the only 
technique used for the analysis of the data. This necessitated a considerable 
refinement of the method: use of a wider spectrum of modern statistical techniques 
and development of quantitative measures of exposure for subpopulations [Gibiansky 
et al, 1997]. The fourth section of Chapter 2 (Section 2.4) supports the model-free 
approach by an extensive simulation [Gibiansky et al, 1999].
Chapter 3 is devoted to two applications of the Nonlinear Mixed Effect methodology. 
In the first section (Section 3.1), a population pharmacokinetic model for one of the 
drugs described in Chapter 2 is developed. To find a form of the structural model, 
individual pharmacokinetic models are first developed for data from phase I 
pharmacokinetic studies using compartmental modelling [Gibiansky, 1995; Nedelman 
et al, 1997a]. These data and patient data used in Chapter 2 are then used for the
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development of the population model [Nedelman et al, 1996]. Initial values of the 
population parameters are obtained by the two-stage method [Gibiansky, 1994]. After 
model development is completed, simulations are used to assess the bias and precision 
of the model parameters. The developed model is used to help design subsequent 
studies for the drug [Gibiansky, 1996].
In the second section of Chapter 3 (Section 3.2), the Nonlinear Mixed Effects 
Methodology is used to develop a population dose-response model of a drug. The drug 
was given to hypertensive patients to reduce their diastolic blood pressure (DBF). If a 
patient did not respond (i.e. his/her blood pressure did not drop below a pre-specified 
threshold after a pre-specified time), the dose for that patient was increased or a dose 
regimen was changed. Thus, different patients received different doses of the drug 
during the trials. Only the patients most resistant to the therapy received the highest 
doses. In this chapter development of the population model of change in DBF 
depending on dose is described. During the trials more cardiovascular adverse events 
were seen among African-American patients than among Caucasians. Therefore, these 
subpopulations are thoroughly investigated in covariate models. Structural model 
relationships were sought among step, linear and sigmoid [Gabrielsson & Weiner, 
1997] models. The best structural models turned out to be different for different races.
Finally, Chapter 4 concludes the work by summarising results of all investigations 
described in Chapters 2 and 3. The results of the model-free approach of Chapter 2 
and model-based approach of Chapter 3 are compared. Differences and similarities of 
these approaches are discussed.
1.8 Tools
Software is an essential tool in this work. The main software packages used in the 
work include SAS® [SAS Institute Inc., 1990], S-PLUS [1997] and NONMEM 
[1992]. SAS was used throughout the work for data management and conventional 
statistics. It was also used for the development of the spline-partitioning technique 
described in the Sections 2.2, 2.3 and 2.4 of Chapter 2, and for the compartmental 
modelling and simulation of Section 3.1 of Chapter 3. S-PLUS is a very powerful tool 
for modern statistical techniques, exploratory graphics and visualisation of data. It was 
used for tree-based modelling, robust regression and simulation in the Sections 2.3
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and 2.4 of Chapter 2, for exploratory graphics and statistical computing in the Section 
3.2 of Chapter 3. NONMEM today is a gold standard in the pharmaceutical industry 
for the nonlinear-mixed effect modelling. It was used for model development in the 
projects of Chapter 3.
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2 MODEL-FREE POPULATION PHARMACOKINETICS
One of the goals of pharmacokinetics is to characterise the relationship between the 
pharmacokinetic parameters of a drug and covariates (such as demographic, disease- 
related, etc.) that alter patient's drug exposure (e.g., AUC). In many situations, finding 
such factors and quantifying the differences in exposure in subpopulations is the main 
goal of the investigation. A model-free approach deals with such situations 
[Gibiansky, et al., 1997; Nedelman, et at., 1995, 1996]. The basic idea of the approach 
is to classify patients into groups according to their exposure and then use various 
statistical techniques to explore association of these groups with covariates. In the 
following three sections this model-free approach is applied to three situations, each 
time the method is more refined and modified to the needs of each project. In the 
fourth section the developed technique is tested on simulated data.
2.1 Anxiolytic Compound
2.1.1 BACKGROUND
As part of the development of a new anti-anxiety drug, there was a need to estimate 
the systemic exposure to the drug (i.e. AUC of the drug in plasma) from phase III 
clinical trials (large-scale safety and efficacy trials in patients). In the trials, patients 
received the drug three times a day for six weeks. Plasma samples were drawn once a 
week at times chosen by the patients. Evaluating pharmacokinetics from such sparse, 
arbitrarily timed plasma samples is known as a pharmacokinetic screen [Steimer, et 
al., 1994].
2.1.2 DATA
The data was obtained from two phase III trials in patients with generalised anxiety 
disorder. The patients received their medication orally at home three times a day, but 
not on a rigid 8-hour schedule. Patients were randomised to different treatment groups 
and were titrated up (i.e. dose was slowly increased) to the target dose (within a given 
treatment) over the first few days of the study. The final daily doses ranged from 3 mg 
to 22.5 mg across treatment groups. Figure 3 displays the distribution of daily doses in 
the two studies.
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Figure 3.
JB 
Frequency distributions of prescribed daily doses, after titration and 
during the time when blood draws were performed, in the two patient 
studies, Study I" , and Study II
Some of the daily doses were non-uniformly distributed between the three 
administrations. For example, a frequent daily dose of 17.5 mg was divided into 5 mg 
in the morning, 5 mg in the afternoon, and 7.5 mg in the evening. The patients took 
their medication at home, and maintained a diary recording the doses they took at each 
administration, but did not record the time.
Patients returned to their physicians for an evaluation once a week for 6 weeks. 
During the weeks 3-6, after the titration period, a blood sample was taken during the 
patient's visit to the clinic. The time of the visit and the time interval since the last 
administration of the drug (time post-dose) were not controlled but rather were 
determined by the patient's choice of when to take the drug and visit the clinic. When 
blood was sampled, patients were asked how long it had been since their most recent 
administration of the drug and since the second most recent. Thus, for each patient, in 
addition to a weekly diary record of dosages, a report from memory of the times of the 
two most recent drug administrations was available. Table 1 displays the numbers of 
patients and numbers of blood samples available for analysis.
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Table 1 Numbers of patients and plasma samples
Study
I
II
Number of patients
87
170
Number of samples
274
562
2.1.3 OBJECTIVES
The goal of this investigation was to characterise the average exposure to the drug and 
relate it to demographic predictors, i.e. identify covariates that affect the exposure to 
the drug. Demographic covariates chosen for exploration of their relationships to 
exposure were age, gender, race, weight, height, body surface area and smoking.
2.1.4 METHODS
The method is based on partitioning observed plasma concentrations into several 
regions, called observation levels, taking into account time of concentration 
measurements. Patients are then partitioned into exposure levels depending on which 
observation level their concentrations fall into. Exposure level serves as a new 
response, an ordered factor that characterises the exposure to the drug. It can be 
explored for an association with covariates.
First, observed plasma concentrations are partitioned into quartiles. This partitioning 
involves several steps:
1. Concentrations are normalised for dose, using weighted average dose
WDOSE. Because it was common to have non-uniform dosage regimens with 
a cycle of three dose levels during a day, WDOSE accounted for three doses 
prior to blood sampling: Dl - the last dose, D2 - second-to-last dose, and D3 - 
third-to-last dose. Weights were chosen to give more importance to more 
recent doses:
WDOSE = (4D1 + 2D2 + D3)/7. Eq. 9
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Previous pharmacokinetic studies [Krause, 1991; Krause, et at., 1990] of the 
drug had indicated that concentrations vary proportionally to dose. Dose- 
normalisation permitted us to combine observations from many dose levels.
A scatter plot of dose-normalised concentrations versus time post-dose was 
considered. Most concentrations were obtained within 0 to 8 hours post dose; 
few concentrations obtained later than 8 hours were excluded from the 
analysis. The time axis was divided into one-hour time intervals from 0 to 8 
hours post-dose.
Within each one-hour interval, the quartiles of the dose-normalised 
concentrations were determined. Figure 4 shows four piecewise constant 
functions that within each one-hour interval take on the values of the four 
quartiles. These functions thus divide the scatter plot of points into four areas, 
which are called observation levels.
2
1
0
" : ii^4^ii''  
--i . i f
Figure 4. Dose-normalised plasma concentrations from the two patient studies, 
with piece-wise constant functions of hourly quartiles of observations. 
Regions between step functions are defined to be observation levels.
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Then patients are partitioned into exposure levels depending on which observation 
levels their dose-normalised concentrations fell into. This process is schematically 
depicted in Figure 5. One can distinguish four different situations:
A. If all of a patient's observed dose-normalised concentrations fall into one 
observation level, the patient is then called an 'all-in-one' patient and is 
assigned to the corresponding exposure level (Figure 5A).
B. Suppose that a patient's dose-normalised concentrations fall into two adjacent 
observation levels. Let u out of n observations for the patient, be in the upper 
of the two adjacent levels and n-u in the lower. Let di, ...,du , be the distances 
from the points in the upper level to the common boundary, and let d u+i, ... , d 
n be the distances for the points in the lower level. If
then the patient is assigned to the exposure level corresponding to the upper 
observation level; otherwise, the reverse.
In Figure 5B, n = 4, u = 2, and since the two points in the third observation 
level are farther from the common boundary than are the two observations in 
the second level, the patient is assigned to the third exposure level.
C. If a patient's dose-normalised concentrations fall into either the first to third 
observation levels or else the second to fourth observation levels, such 'three- 
adjacent' patient is assigned to the exposure level corresponding to the middle 
of the three observation levels (Figure 5C).
D. If a patient has dose-normalised concentrations spanning the first and fourth 
observation levels, then the patient is called an 'all-four' patient and is 
considered not to represent a stable type. Such patient is left unclassified as to 
exposure level (Figure 
Figure 5. Dose-normalised plasma concentrations for fictitious patients:
illustration of assignment algorithm. Patient observations fall in A 
one observation level, B - two adjacent regions, C -three adjacent 
regions, D - four observation levels.
This classification provides a crude estimate of exposure for each patient; the 
exposure level to which a patient is assigned is an ordinal measure of the patient's 
dose-normalised exposure to the drug.
The choice of the observation levels and the exposure measure in the model-free 
approach is somewhat arbitrary. The four observation levels used in this work were 
chosen by the analogy with four quartiles commonly used in the statistical analyses. 
One can use an ordinal measure based on more observation levels or create a 
continuous measure. For example, some average (over the subject's measurements) of 
standardised distances of the subject's measurements from the average population 
concentrations within the respective time intervals may serve as such a measure. The
rule of subject's assignment to the exposure level is not unique as well. One can 
imagine more elaborate schemes. As one will be able to see, the present choice made 
it possible to obtain meaningful results. More experiments may be needed to find the 
best possible exposure measure within the model-free framework. This work focuses 
on obtaining practical results and proving of method's concept with the chosen 
exposure measure rather than experimenting with various possible alternatives.
To find predictors that affect exposure, exposure levels are related to demographic 
covariates by standard statistical techniques: contingency-table analysis for the 
categorical covariates such as smoking, gender, and race; ANOVA for the continuous 
covariates such as age and measures of body size.
For comparison of model-free and model-based results, discussed later, a quantitative 
measure of an individual exposure, a quartile-based analogue of the AUC, was 
created. It is called the area under the quartile, or AUQ.
To compute an AUQ for each patient during each week, a number called a dose- 
normalised AUQ is first associated with each exposure level. Figure 6 shows how 
such a number is computed for the third exposure level. The shaded area is the area 
under the function that defines the middle of the third observation level, the fifth 
octile. For the first, second and fourth exposure levels, the first, third and seventh 
octiles are used, respectively.
An AUQ for a given patient in a given week is then computed by multiplying the 
patient's average weighted dose WDOSE times the dose-normalised AUQ for the 
patient's exposure level.
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Figure 6. Definition of the dose-normalised area under the quartile for the 
exposure level. Shaded is AUQ for he third exposure level. Thick solid 
lines denote boundaries of the exposure levels.
2.1.5 RESULTS
Table 2 shows the frequency distributions of the four types of patients in each study. 
The observation levels were determined from the data from the two studies combined; 
the purpose of the separation in Table 2 is to check whether there is any large 
difference between the studies with respect to frequencies of types. The frequencies 
show that 80 percent of subjects were in the two most stable types, all-in-one and two- 
adjacent. Only 3 per cent were not classified because of having dose-normalised 
concentrations in both the first and fourth observation levels. Results confirm that 
patients were similar in two studies with respect to their types; there were no large 
differences in the frequencies of types in these studies.
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Table 2. Frequencies of patient types
Type
Frequency 
(Col %)
Study I Study II Total
All-in-one
41
47%
68
40%
109
42%
Two-adjacent 26
30%
69
41%
95
37%
Three-adjacent 17
20%
28
16%
45
18%
All-four
3
3%
5
3%
8
3%
Total 87 170 257
Table 3 shows the distribution of patients among exposure levels. Due to the way that 
exposure levels are constructed, there is no constraint that the patients partition 
uniformly among them. Despite this, the distribution across the four levels of 
classified subjects is fairly uniform. Furthermore, patients were similar in the studies; 
there are no large differences between the studies in frequencies of assigned exposure 
levels.
Table 3. Frequencies of exposure levels
Exposure level
Frequency 
(Col %)
Study I Study II Total
Unclassified
3
3%
5
3%
8
3%
1
17
20%
37
22%
54
21%
2
16
18%
48
28%
64
25%
3
30
35%
45
27%
75
29%
4
21
24%
35
21%
56
22%
Total 87 170 257
Table 4 contains the main results of the project. Specifically, it summarises the results 
of the univariate statistical analysis. Each covariate was tested separately. For 
categorical covariates the null hypothesis of no difference was tested against a two- 
sided alternative hypothesis of a difference in exposure level depending on the level of 
covariate. For continuous covariates the null hypothesis was the hypothesis of no 
difference in means of the covariate between different exposure level groups. Testing 
was performed at the 95% significance level. The contribution of each covariate to the 
exposure level is presented in terms of the p-values, with p < 0.05 being regarded as 
significant, p < 0.01 more significant, and p < 0.001 regarded as highly significant. 
The direction of the influence is also shown. As can be seen, smoking, gender and age 
are found to be significantly related to exposure; with smoking being the most 
important factor followed by gender, and then by age. Smoking decreased exposure 
levels, whereas age increased the levels. Females tended to be in higher levels. Neither 
race nor any measure of body size was significantly related to exposure level.
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Table 4. Relationships between demographics and exposure.
Covariate Contribution
Direction of effect 
on exposure level
Smoking
Gender (female)
Age
Race
Weight
Height
Surface Area
+++
++
+
-
-
-
-
;
t
t
- p>0.05, + p<0.05, ++p<0.01,    p< 0.001.
Figure 7 Model-free AUQs versus model-based AUCs.
These results are reported in Nedelman et al [1995], where they were used in the 
model-based analysis of the drug's pharmacokinetics. The covariates found to be 
important by the model-free method were incorporated into the nonlinear mixed effect
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model. The model (not described in this thesis) confirmed the findings of the model- 
free approach. Apparent oral clearance increased in smokers, and decreased in females 
and with increasing age. The contribution of these covariates followed the same order 
as in model-free approach. Figure 7 shows a strong linear correlation between model- 
free AUQs and model derived AUCs.
2.2 Antifungal Compound
2.2.1 BACKGROUND
The second project is devoted to an anti-fungal drug. Pharmacokinetic studies have 
revealed that this drug has a prolonged half-life ranging from 4 to 22 days 
[Faergemann, et a/., 1991; Jensen, 1989, 1990]. This long half-life may cause marked 
accumulation of the drug over the 6 to 24 weeks of administration. Long-term 
exposure to high levels of the drug might alter the risk/benefit ratio of treatment with 
this agent. Consequently, the investigation was undertaken to identify demographic 
predictors of its exposure and to explore whether increased exposure or demographic 
predictors of increased exposure were associated with altered safety or efficacy in 
patients.
2.2.2 DATA
Data was obtained from two efficacy and safety studies (PI and P2) in patients with 
onychomycosis. Patients were directed to take one tablet daily, either placebo or the 
drug. Dosing continued for 24 weeks in Study PI and 12 weeks in Study P2. In each 
study, there were three treatment arms. One arm received placebo for the entire 
duration of dosing. The second arm received active drug at 250 mg/day for the entire 
duration of dosing. A third arm received active drug at 250 mg/day for the first half of 
the dosing period (12 weeks in Study PI and 6 weeks in Study P2) followed by 
placebo for the second half. Sparse pharmacokinetic samples were obtained in these 
efficacy studies. Maximally three plasma samples were collected per patient during 
the study. One sample per patient was drawn when the patients visited their physicians 
at weeks 4, 12, and 24 in Study PI, and weeks 4, 6, and 12 in Study P2. The times 
during the day of the patients' appointments, and consequently, the times post dose of 
the blood samples, were not specified in the protocol but rather were determined 
solely by the patients' and investigators' convenience - i.e., they were, in the sense of 
population screens, "random". Patients kept diaries recording the times of doses taken 
on the two evenings prior to blood sampling. Investigators recorded the times of the 
blood samples.
In both studies, the times post dose at which the blood samples were drawn generally 
fell into three major groups: around 15 hours, 1000 hours, and 2000 hours post dose
as shown in Figure 8. Indeed, since doses were taken in the evening before the day of 
the visit to the physician, blood samples were usually taken around 15 hours after the 
tablet was ingested. The second cluster at around 1000 hours comes from the blood 
samples at 12 weeks from those patients in Study PI who received the drug for only 
the first six weeks. The third cluster at around 2000 hours comes from the blood 
samples at 24 weeks from those patients in Study P2 who received the drug for only 
the first 12 weeks.
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Figure 8. Concentration versus time data for studies P1 and P2 (points) on the 
log scales. Superimposed are three splines that define partition 
boundaries.
In total, 545 plasma concentrations were available: 327 observations from 130 
patients in Study PI and 218 observations from 89 patients in Study P2. Among them, 
29 samples had zero concentrations, i.e. concentrations below the quantification limit 
of the bioanalytical assay (BQL). They were excluded since a log scale for 
concentrations was used. Two more observations were eliminated because they were 
obvious outliers. The resulting data set had 514 observations.
2.2.3 OBJECTIVES
As before, the goals of the model-free population pharmacokinetic analysis were to
partition patients into exposure levels, and subsequently explore the relationship
between the covariates and exposure levels. It was decided in advance to restrict 
consideration to the following covariates:
Demographic: age, sex, race, weight, body surface area, and smoking status; 
Lipid levels: LDL (low-density lipoprotein cholesterol) concentration; 
Medical conditions: hypertension, peripheral vascular disease.
2.2.4 METHODS
Unlike the previous project, the data was very non-uniformly distributed across time. 
There were clusters of many points and there were extended intervals with few or no 
points. Consequently, use of a piecewise constant function at equal intervals, to 
partition plasma concentrations into quartiles, was not possible. Any other arbitrary 
chosen division of time intervals (for example, intervals with equal numbers of points) 
was also questionable. Due to the temporal variations of the plasma concentration 
data, lumping together distant points was also inappropriate. As a result, interpolation 
of the data was used. In particular, nonparametric smoothing splines were used to 
separate observation regions instead of piecewise constant functions (see DeBoor, 
1978 for a detailed description of smoothing splines or a brief Remark below).
Remark:
Suppose one has a scatterplot of n pairs (xit yj. Among all functions f(x)
with two continuous derivatives, a smoothing spline minimises a penalised 
residual sum of squares
where A, is a fixed constant, called a smoothing parameter, and a <xj <... <xn 
<b. The solution is a natural cubic spline with knots at the unique values ofx, 
(i.e. Xj *Xj for any pair of knots x* Xj) . The smoothing parameter A. controls 
the fit. At the one extreme, as A -» 0, the penalty term dominates, forcing 
f(x) = 0 everywhere, and thus the solution is the least-squares line. At the 
other extreme, as A, -> oo, the penalty term becomes unimportant and the 
solution tends to an interpolating twice-differentiable function. The
smoothing spline is a powerful and flexible form of non-parametric regression 
technique based on strictly interpolating splines [Silverman, 1985].
To partition plasma concentrations into observation levels a nonparametric cubic 
smoothing spline is fitted through the scatter plot of concentration versus time for all 
patients, all visits and studies together, as in Figure 8. The resulting curve estimates 
"typical" plasma levels as a function of time, dividing the scatter plot into two parts, a 
higher and a lower. Then the same nonparametric smoothing is applied separately to 
each of the two parts. The resulting curves estimate "typical" lower and upper 
concentrations as functions of time. The three curves, three partition boundaries, 
divide the points into four regions, four observation levels. Each of these four regions 
do not necessary contain 25% of the observations, as in the previous project. The less 
uniform the concentrations are distributed at each time interval, the further the regions 
are from the quartiles.
Fitting a smoothing spline involves an arbitrarily assigned value of the smoothing 
parameter A,. The greater the parameter the smoother the fitted curve is. Several values 
of A, were used, based on experimentation with the smoothing algorithm.
The smoothing was to be applied to a scatter plot of concentration versus time post 
dose. However, both concentrations and times post dose ranged over several orders of 
magnitude, so the linear scales of concentration and time might not be the most 
convenient. Log-transformed concentrations were used on the y-axis. On the x-axis, 
both log-transformed and untransformed raw times were tried.
The duration of treatment from the first dose until the plasma sample was drawn 
ranged from 4 to 24 weeks. It was suspected that the drug might accumulate in the 
blood over such periods. In this case, in order to standardise the concentration values 
during different weeks of dosing, the concentrations should be adjusted for the 
expected accumulation. Both variants, with and without adjustment, were tried. In one 
variant, the concentrations were left unadjusted for accumulation. In the other variant, 
they were adjusted by dividing concentrations by a pseudo-accumulation factor,
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where d is the number of days of dosing prior to the blood sample, and b is an 
estimate of a parameter that characterises a half-life. Two values of b were used: 
0.00165 and 0.0019. This parameter comes from the compartmental modelling and it 
is described later in Chapter 3 (where it was denoted b4).
Not all possible combinations of the preceding options regarding smoothing 
parameter, axis scales, and adjustment for accumulation were used. Complete analyses 
were conducted using five different combinations of options. Table 5 exhibits those 
combinations.
Table 5. Combinations of parameters used for partition
Combination
Transformation 
of time
b4
Smoothing 
parameter
1
2
3
4
5
none
log
log
log
log
0.0019
0.0019
0.0019
none
0.00165
10,000,000
0.1
1.0
1.0
1.0
After observation levels are determined, patients are assigned to the exposure levels 
according to the same algorithm as in the previous project. Thus, in the modified 
partitioning method piecewise constant boundaries of the observation levels are 
replaced by smooth functions of time, namely smoothing cubic splines.
A statistical analysis was performed to explore the association between the exposure 
levels and the covariates. The categorical covariates used in the analysis were gender, 
age (divided at 40 years from the previous experience with the drug), race, smoking, 
history of hypertension, and history of peripheral vascular disease. The continuous 
covariates were age, weight, body surface area and LDL cholesterol level. Age was 
used both as a continuous and categorical covariate.
For each categorical covariate, frequency tables were generated and the Fisher's exact 
test was applied. The null hypothesis of no difference was tested against a two-sided 
alternative hypothesis of a difference in exposure level depending on the level of the 
covariate. Testing was performed at a 95% significance level.
For continuous covariates, the distribution of the covariate by exposure level was 
summarised by means and standard deviations. Furthermore, the mean of each 
continuous covariate was compared across the exposure levels by an analysis of 
variance (ANOVA), in which the null hypothesis of equality of the means was tested 
against an alternative that the means either increased or decreased linearly with the 
exposure levels.
It is important to note that not all of the covariates are independent. It is known that 
weight and body surface area differ for men and women; interaction of cholesterol 
level and age in the studies with gender could also be suspected. For a continuous 
response variable a natural choice of analysis would be to perform a two-way 
ANCOVA, with gender and a covariate in the model. The exposure level, however, is 
not a continuous variable. Therefore, in order to account for possible confounding of 
the effect of the covariate on the exposure level by gender, the two-way ANOVA with 
gender and the exposure level as the main effects of the model was performed for all 
continuous covariates. The interaction term was also included.
Also, to account for the fact that cholesterol generally increases with age [Braunwald, 
et al., 1987] a two-way ANOVA was performed for cholesterol level with age, the 
exposure level, and their interaction included in the model. As with the categorical 
covariates, testing was performed at a 95% significance level.
The partition algorithm, described above, was implemented in SAS and SAS/IML 
language [SAS Institute Inc., 1989a]. The SAS/IML function SPLINEC was used for 
spline fitting. The statistical analysis was implemented using SAS/STAT [SAS 
Institute Inc., 1989b].
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2.2.5 RESULTS
Figure 8 shows the scatter plot of log concentrations versus log time with the partition 
boundaries resulting from combination 4 of the parameters (see Table 5). The other 
combinations produced similar plots.
Table 6 displays the percentage of observations assigned to each of the four 
observation levels by each Combination of options. As can be seen, five 
Combinations yield similar partitions. As expected, the method did not partition the 
observations into four equally sized groups; the first and the fourth observation levels 
have slightly less observations than the second and the third levels.
Table 6. Frequencies of observation levels
Combination
Observation Level
1 2 3 4
1
2
3
4
5
22%
21%
21%
23%
21%
28%
27%
28%
30%
28%
29%
29%
29%
27%
29%
21%
23%
22%
21%
22%
Table 7 displays the distribution amongst the exposure levels generated by each of the 
five combinations. The five distributions are similar, with combination 4, where no 
adjustment for accumulation was made, being the most different. Only 4% of patients 
have not been assigned to the exposure levels because they had plasma levels in both 
the first and fourth observation levels. As with the observation levels, the distributions 
of patients are not uniform over the four exposure levels. The differences between the 
first and fourth exposure levels relative to the second and third are more pronounced 
than with the observation levels. This suggests that many patients had occasionally but 
not consistently high or low plasma levels.
Table 7. Frequencies of exposure levels
Combination
Exposure level
1 2 3 4 Unassigned
1
2
3
4
5
16%
15%
15%
18%
15%
34%
35%
35%
33%
35%
29%
30%
30%
31%
30%
17%
16%
16%
14%
16%
4%
4%
4%
4%
4%
Table 8 displays the distributions of patients according to the spread of their plasma 
levels among the four observation levels. The results are generally similar, with 
combination 4 again differing most from the others. On average, 35% of the patients 
were in the most consistent All-in-One category, and another 41% were in the 
Two-Adjacent category.
Table 8. Frequencies of patient types
Combination
Patient Type
All-in- 
One 8
Two- 
Adjacent 6
Three- 
Adjacent 0
All- 
Four'1
1
2
3
4
5
33%
32%
31%
47%
31%
42%
41%
43%
35%
44%
21%
23%
21%
15%
21%
4%
4%
4%
4%
4%
a) All concentrations in one observation level
b) All concentrations in two adjacent observation levels
c) All concentrations in three adjacent observation levels
d) Concentrations span four observation levels
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Table 9. Frequencies of gender and race versus exposure level
Exposure 
level
Total
Gender 
(Row %)a
Male Female
Race
(Row %)a
Caucasian Black Oriental Other
Unassigned
1
2
3
4
9
33
76
65
36
89%
85%
84%
85%
89%
11%
15%
16%
15%
11%
78%
97%
91%
88%
89%
0%
0%
0%
2%
3%
0%
0%
0%
2%
3%
22%
3%
9%
9%
6%
a) Computed as percent of a cell frequency to the Total in the corresponding exposure level
Table 10. Frequencies of age versus exposure level
Exposure 
level
Total
Age in years
40 and under
Total under 
Male 
40
N % a %b
Female
%b
over 40
Total over 
40
N % a
Male
% c
Female
% c
Unassigned
1
2
3
4
9
33
76
65
36
4
19
27
15
4
44%
58%
36%
23%
11%
75%
79%
78%
80%
100%
25%
21%
22%
20%
0%
5
14
49
50
32
36%
42%
64%
77%
89%
100%
93%
88%
86%
88%
0%
7%
12%
14%
13%
a) Computed as percent of a cell frequency to the Total in the corresponding exposure level;
b) Computed as percent of a cell frequency to the Total under 40 in the corresponding exposure level;
c) Computed as percent of a cell frequency to the Total over 40 in the corresponding exposure level.
Table 9 - Table 15 display the distributions of covariates by exposure levels: Table 9 
Table 11 show frequencies of categorical covariates; Table 12 - Table 15 display 
means and standard deviations of quantitative covariates. From the results presented 
for categorical covariates, it is evident that gender, race and a history of vascular 
disease does not influence the assignment to the exposure level: the percentage of
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males, Caucasians or patients with vascular disease does not change with the exposure 
level. Age, smoking and a history of hypertension appear to have an effect on 
exposure: percentage of patients over 40 years old, non-smoking patients and patients 
with the history of hypertension increases with the exposure level. From the tables for 
the continuous covariates, mean age increases with the exposure level. There is also a 
slight increase in LDL for women. Means of weight and body surface area do not 
change across the exposure levels.
The exposure level assignments in the Table 9 - Table 15 are from combination 3. The 
results of the other combinations are similar.
Table 11. Frequencies of smoking, vascular disease and hypertension versus 
exposure level
Exposure 
level
Total
No. of cigarette packs 
per day
0 <1 1-2 >2
Vascular 
disease
No Yes
Hypertension
No Yes
Unassigned
1
2
3
4
9
33
76
65
36
100%
73%
80%
83%
97%
0%
12%
14%
8%
3%
0%
15%
5%
8%
0%
0%
0%
0%
2%
0%
100%
97%
99%
98%
97%
0%
3%
1%
2%
3%
89%
100%
93%
88%
78%
11%
0%
7%
12%
22%
Table 12. Means and standard deviations of age versus exposure level
Exposure 
level
Age (years)
Total
Mean Std
Male
Mean Std
Female
Mean Std
Unassigned
1
2
3
4
44.9
41.9
46.1
50.5
55.7
16.1
12.0
11.9
11.8
11.8
46.6
42.6
46.3
50.2
55.5
16.3
12.1
12.4
11.4
12.4
31.0
37.8
44.6
51.8
57.3
0
12.0
8.4
14.5
5.1
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Table 13. Means and standard deviations of weight versus exposure level
Exposure 
level
Baseline Weight (kg)
Total
Mean Std
Male
Mean Std
Female
Mean Std
Unassigned
1
2
3
4
80
82
77
83
81
16
18
13
16
16
83
84
80
87
83
14
15
11
14
16
58
68
65
62
65
0
29
17
7
14
Table 14. Means and standard deviations of body surface area versus exposure 
level
Exposure 
level
Body surface area (m2)
Total
Mean Std
Male
Mean Std
Female
Mean Std
Unassigned
1
2
3
4
2.0
2.0
1.9
2.0
2.0
0.2
0.3
0.2
0.2
0.2
2.0
2.1
2.0
2.1
2.0
0.2
0.2
0.2
0.2
0.2
1.7
1.7
1.7
1.7
1.7
0
0.4
0.2
0.1
0.2
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Table 15. Means and standard deviations of low-density lipoprotein cholesterol 
(LDL) versus exposure level
Exposure 
level
Baseline LDL level (mg/mL)
Total
Mean Std
Male
Mean Std
Female
Mean Std
Unassigned
1
2
3
4
3.1
3.2
3.3
3.5
3.3
0.6
0.7
0.9
1.2
1.0
3.2
3.2
3.3
3.4
3.3
0.6
0.7
1.0
1.2
1.0
2.6
2.6
3.1
3.6
3.8
0
0.8
0.9
0.9
0.2
Table 16 contains the main results of the analysis. Specifically, it summarises the 
results of inferences regarding relationships between the exposure level and the 
covariates for each of five combinations. Each covariate was tested separately as 
described in the Methods (Section 2.2.4). Contribution of each covariate to the 
exposure level is shown in the table in terms of the p-values with p < 0.05 being 
regarded significant, p < 0.01 more significant, and p < 0.001 regarded as highly 
significant. The direction of the influence is also shown.
As can be seen, the five combinations agreed on the importance of smoking and age as 
correlates of the exposure level. Four of five combinations also recognised 
hypertension as a significant covariate. Sex, race, history of vascular disease, lipid 
level (LDL), and two measures of body size (weight and surface area) were all found 
not to be significantly associated with the exposure level. Smokers generally had 
lower plasma levels; older patients and patients with hypertension (of which there 
were only 24) generally had higher plasma levels.
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Table 16. Relationships between demographics and the exposure level for five 
combinations.
Covariate
Contribution
Combination
1 2 3 4 5
Direction of effect on 
exposure level
Smoking
Age (>40)
Age
Hypertension
Gender
Race
Vacular disease
Weight
Surface Area
LDL
+
+++
+++
+
-
-
-
-
-
-
+
+++
+++
+
-
-
-
-
-
-
+
+++
+++
++
-
-
-
-
-
-
++
+++
+++
-
-
-
-
-
-
-
+
+++
+++
++
-
-
-
-
-
-
4-
t
t
t
- p>0.05, + p<0.05, p<0.01; +++ p< 0.001.
The results of this analysis were used in the model-based analysis of the drug 
discussed in Section 3.1.3 of Chapter 3. The covariates found to be important by the 
model-free method were incorporated there into the nonlinear mixed effect model.
2.3 Antiplatelet And Vasodilative Agent
2.3.1 BACKGROUND
The third analysis deals with a drug indicated for treating the symptoms of 
intermittent claudication. The drug increases the distance that patients can walk before 
pain prevents their motility.
The aim of the pharmacokinetic analysis of phase III safety and efficacy studies, was 
to identify covariates affecting patients' exposure to the drug and to quantify the 
influence of these covariates.
Analysis of phase I pharmacokinetic data of the drug showed proportional increases in 
AUC, and less than proportional increases in Cmax, following single doses across the 
dose range of 50-200 mg. The time to plasma maximum concentration (tmax) and the 
terminal half-life were approximately 3 hours and 12 hours respectively, and were 
similar across the doses. Following multiple administration of a 100 mg dose, twice-a- 
day (b.i.d.), steady-state plasma concentrations were achieved within 4-5 days. When 
administered under fed conditions, there was an increase of approximately 50% in the 
Cmax and an increase of 25% in the AUC.
Plasma concentration-time profiles after a single dose or after discontinuing a 
multiple-dose regimen had irregular secondary peak(s), as shown in the Figure 9 at 20 
- 25 hours post dose for approximately 70% of subjects.
A nonparametric approach for the population analysis was further developed and 
applied to the data of the project.
10OO -,
Figure 9. Plasma concentration versus time after last dose for a typical subject 
after eight days of dosing.
2.3.2 DATA
Data come from four randomised, double blind, efficacy and safety studies (I, II, III 
and IV) in patients with intermittent claudication. Walking distance at baseline 
measured on a treadmill, was one of the main criteria for inclusion in the studies. 
Drug (100 mg daily) or placebo was administered for 12, 16 or 24 weeks twice-a-day 
(bid), once in the evening and once in the morning, half an hour before the meal. 
Patients were evaluated every two to four weeks during their visit to the clinic. They 
had to skip their morning dose at the day of the visit (for morning visits), or take their 
dose early morning before the afternoon visit. Patients had to come to the clinic for 
'trough' (at the end of dose interval, right before the next dose) evaluation always 
around the same time. At some visits in some of the studies, 'peak' evaluations were 
also performed. For 'peak' evaluation, patients had to take the drug immediately after 
the 'trough' evaluation and be evaluated 2-4 hours later. The number of patients from 
each study on a 100 mg dose, the duration of treatment, and the number of plasma 
samples are listed in Table 17.
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Table 17. Number of patients, samples and treatment duration.
Study
No. patients 
on 1 00 mg 
dose
Treatment 
duration 
(weeks)
Samples per patient 
up to
'Trough' 'Peak'
I
II
III
IV
171
95
133
119
24
12
24
16
8
5
3
3
 
2
 
2
Criteria for inclusion and exclusion of patients were similar across the studies except 
for some differences in treadmill set-up and in the baseline walking requirements (See 
Appendix A). In addition, patients in the study II had to complete 3 weeks of low fat, 
low cholesterol diet prior to the study, and had to adhere to the diet during the study.
Blood samples of non-compliant patients were excluded from the analysis. Non- 
compliance was defined prospectively in the clinical protocol. A patient was 
considered non-compliant if he/she took less than 75% of the prescribed drug on 2 or 
more successive visits or had undetectable plasma levels on 2 or more successive 
occasions.
T3 O
Figure 10. Distribution of sampling times between 0 and 50 hours.
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Samples taken later than 20 hours after the last dose were also excluded. There were 
28 samples between 20 and 50 hours, which was insufficient to meaningfully define 
the observation regions (this is discussed later in the Methods, Section 2.3.4). Figure 
10 shows the distribution of sampling times between 0 and 20 hours. In addition, there 
were 39 samples spread from 50 to 3108 hours, which were also excluded from the 
analysis. The details concerning the excluded observations are described in Appendix 
B.
In total, 2161 plasma concentrations from 462 patients were used in the analysis.
2.3.3 OBJECTIVES
As before, the objectives of the model-free population pharmacokinetic analysis were 
to partition patients into exposure levels, and then, explore relationships between the 
covariates and exposure levels. The list of covariates included: 
Demographics: age, gender, race, weight, body surface area, and
obesity;
Lifestyle: alcohol and smoking habits; 
Medical history: myocardial infarction, cerebro-vascular event, and
diabetes;
Disease state: duration of disease and walking impairment at baseline; 
Concomitant medications 
and medical conditions: drugs and therapeutic subclasses of drugs used by at
least 25 patients.
2.3.4 METHODS
The analysis, as described earlier in Section 2.2.4, was based on partitioning plasma 
concentrations into observation levels, and assigning each patient an exposure level. 
An investigation of the relationships between the exposure level and covariates was 
then conducted. Plasma concentrations were partitioned into observation levels and 
patients were assigned to exposure levels following the same procedure as in Section 
2.2.4. Further steps dealing with the relationships between the exposure and the 
covariates, were considerably refined and expanded as presented in the following 
sections.
It was assumed that there was no accumulation of the drug during the studies and the 
disease progression or drug's pharmacological effects did not affect pharmacokinetics 
of the drug. The assumption was supported by phase I studies, where steady state was 
reached by Day 4 of twice-a-day dosing. The earliest plasma concentrations were 
taken after 2 weeks of dosing in phase III studies, so steady-state should have been 
reached by the first evaluation.
In Step I, as before, three nonparametric cubic smoothing splines were fitted through 
the scatter plot of concentration versus time, to estimate partition boundaries as 
functions of time after the last dose. The span of times after the last dose was not as 
large as in the previous project, so there was no need for transformation of times. 
Also, all patients had the same dose throughout all the studies, therefore dose 
normalisation of concentrations was not necessary. Raw concentrations, not their log- 
transformations were used for partitioning. Log-transformation of the concentrations 
in a pharmacokinetic analysis is a customary practice, based on the observation that 
plasma concentrations are often log-normally distributed in the population. 
Transforming the data therefore allows one to make mean-based comparisons using 
the normal theory assumptions. The partitioning algorithm does not use the 
assumption of normality, so there is no theoretical advantage in using transformed 
data. There were no reasons to expect that the results depend on whether log- 
transformed or raw data were used.
The determination of splines depends on the choice of a smoothing parameter. Since 
the choice of this parameter is somewhat arbitrary, three different values of the 
smoothing parameter were used. The set of four regions obtained for each value of the 
smoothing parameter will be further referred to as a Partition set (not a combination as 
in Section 2.3, since only one parameter influenced the partition).
In Step II, patients were assigned an exposure level according to the algorithm 
described earlier. It was done for several Partition sets.
The next step, Step III, relates the exposure levels and variability to covariates. Two 
types of responses were investigated for association with covariates: 1) For patients 
classified into one of four exposure levels, exposure level represented an ordered 
categorical response; 2) High and Low variability was another response variable, a
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categorical response. Patients assigned to one of the exposure levels represented the 
Low variability group, patients from the 'unclassified' group represented the High 
variability group.
Table 18 lists all the covariates, their types and levels (for categorical covariates) that 
were investigated for association with the exposure level and the variability type. Two 
measures of obesity (Obesity, OBES, and %above ideal body weight, PIBW) and body 
surface area (BSA) were computed for each patient from their weight, height and 
gender as follows [Bayley & Briars, 1996; Rowland & Tozer, 1995]:
Ln(BSA) = -3.751+0.422*ln(HGT)+0.515*ln(WGT), Eq. 12
_ 
_ 
_ 
t\
where HOT is height (cm), WGT is weight (kg), and BSA is measured in cm ;
50 + 2.3/2.5* max(0, HOT -152) for males
IBW= Eq. 13
45 + 2.3/2.5* max(0, HOT -152) for females,
and
PIBW = 100 (WGT - IBW) / IBW, Eq. 14
where IBW denotes ideal body weight (kg) and PIBW is percent above ideal body 
weight.
Obesity (OBES) was defined as 0, if PIBW < 20, and 1, otherwise.
Concomitant medications were considered in two ways: grouped by their generic 
name (irrespective of the dose and manufacturer) and grouped by subclasses of major 
therapeutic classes. To be used as covariates, the concomitant medications and groups 
of medications had to be used by more than 25 patients. The cut-off of 25 patients was 
decided prospectively as approximately 5% of initial 518 patients, before cleaning the 
database.
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Table 18 Description of covariates
Covariate Type
Demographics
Lifestyle
Medical history
Disease state
Concomitant 
medications and 
medical 
conditions
Study design
gender, race, obesity (>20% above ideal body weight)
age, weight, body surface area (BSA) , % above ideal 
)ody weight
smoking(never/ previously/current), 
alcohol (never/ previously/current)
diabetes, myocardial infarction, cerebro-vascular event
duration of disease (0.5 to 1; 1 to 5 ; 
5 to 10; >10 years), 
vaseline walking impairment a (Mild/ Moderate/ 
Severe)
drugs and therapeutic subclasses of drugs used by at 
[east 25 patients (Yes/No) 
[ndividual drugs: acetaminophen, nifedipine.
combination vitamins and minerals, lisinopril, 
nitroglycerin, lovastatin, glyburide, enalapril maleate, 
atenolol, furosemide, combination diuretics, verapamil 
lydrochloride, digoxin, gemfibrozil, levothyroxine 
sodium, vitamin e, diclofenac sodium, potassium 
chloride, ranitidine hydrochloride, isophane insulin 
suspension; 
Groups bv therapeutic class: antihistamine drugs,
sympathomimetic (adrenergic) agents, cardiac drugs, 
antilipemic agents, hypotensive agents, vasodilating 
agents, nonsteroidal anti-inflammatory agents, 
antidepressants, benzodiazepines, replacement 
preparations, diuretics (except potassium sparing 
diuretics), antacids and adsorbents, cathartics and 
laxatives, misc. GI drugs, insulins, sulfonylureas and 
thyroid agents
study
Factor
Continuous
Ordered 
categorical
Factor
Ordered 
categorical
Factor
(Yes/No)
Factor
a) Mild - > 200 m; Moderate - from 100 to 200 m; Severe - < 100 m.
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To count the number of patients on a particular medication or a group of medications, 
every patient was assumed to be on a drug, if he/she had at least one plasma sample 
while on that medication. For each drug/group of drugs that was used by 25 or more 
patients, the indicator variable of whether a person was on that medication at the time 
of sampling was recorded for each blood sample.
In total, there were 21 individual drugs and 16 therapeutic subclasses of drugs used by 
25 or more patients.
Multivariate Classification Tree-based analysis (CART]
To account for possible confounding by correlated covariates, a binary classification 
tree was grown by CART methodology using S-Plus (Version 3.3) [Venables & 
Ripley, 1994]. The attractiveness of the tree approach includes the ability to handle 
categorical and continuous variables, interaction between variables and missing values 
of covariates. Also, the tree is invariant to monotone transformations of variables, thus 
relaxing the distributional requirements for independent and dependent variables 
[Breiman et al., 1984]. Following in the Remark is the brief description of the 
methodology:
Remark:
Constructing trees is a modelling technique especially suitable for modelling 
of a categorical response function of several categorical, factor or continuous 
variables. Tree based models seek to partition the space of observations into 
the groups (leaves) that are as homogeneous (with respect to response) as 
possible \vithin the groups, and as heterogeneous as possible between the 
groups. The resulting model consists of a partition of the space of 
observations into a set of leaves and a probability distribution over the levels 
of response variable for each leaf The splitting rules uniquely define the 
leaves. The tree construction process starts with the tree with just one leaf that 
includes all the observational space. The procedure takes the maximum 
reduction in deviance (objective function used for the tree modelling, see 
[Ciampi et al., 1987]) over all allowed splits of this initial leaf to choose the 
first split. The procedure is repeated until the number of observations in each 
leaf or its deviance is small. The tree grown by this procedure may overfit the 
data; i.e. may describe the training data set well while not adequately
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describing a new data set. The pruning procedure [Breiman et al, 1984], a 
methodology analogous to model selection in regression, obtains an optimal 
subtree by minimising a cost-complexity measure (a sum of the deviance and a 
term proportional to the tree size) of a sequence of subtrees. An even better 
way is to grow the tree on one set of data and test it on a different set of data 
(external validation) or to split the data to use different data for building and 
predicting (internal validation). A detailed description of the tree-based 
modelling methods can be found, for example, in [Clark & Pregibon, 1992].
Separate trees were grown for each of three partition sets. Each tree was then pruned 
and cross-validation was performed [Venables & Ripley, 1994]. For cross-validation, 
the data set was randomly divided into 10 subsets, the tree was grown for each 9710th 
of the data, and the sequence of pruned trees was tested on the remaining 1710th . 
Averaging over ten trees for each pruning size gave a cross validated plot of deviance 
as a function of the tree size. The tree size that corresponded to a minimum deviance 
was considered to be optimal. An overparametrised model (i.e., the model with 1-2 
more terminal nodes than in the optimal tree) was considered for further exploration 
of subpopulations. The goal of allowing 1 -2 more covariates than in the optimal tree 
was to check that those covariates (less important according to the tree) would not be 
significant in further explorations. This would ensure that the tree model captured all 
the important covariates.
Univariate analyses
For the covariates identified as significant by the tree models, nonparametric
Spearman rank correlation analysis [Snedecor & Cochran, 1980] and subgroup
analysis of association between the covariates and response were performed.
Subgroups were defined by the tree models and by the correlation between the
covariates.
Table 19 describes the types of nonparametric association tests used for different types 
of variables. The purpose of this analysis was two-fold: first, it was aimed to formally 
confirm the results of the tree-based analysis of association of covariates with the 
exposure level for patients classified to an exposure group. Second, for all patients, 
the analysis was to test the association between patient's variability type (High/Low) 
and the covariates.
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Table 19. Univariate analysis
Data used
Response
Type Variable
Covariate
type
Analysis Reference
All patients
except
unclassified
All patients
Ordinal
Categorical
Exposure
level
Variability
type
Categorical
Continuous
Categorical
Continuous
van Elteren
test
Jonckheere's
test
Fisher exact
test
tables of
means and
standard
deviations,
side-by-side
box plots
Lehmann, 1975
Hollander, Wolfe,
1 973; Morris, Dietz,
1989
Kendall, Stuart,
1979; Mehta, Patel,
1983
After the tree models identified influential covariates it was important to estimate the 
clinical, not statistical importance of these covariates. Therefore, it was important to 
quantify the effect of covariates. This was done in Step IV.
In Step IV, scatter plots of concentrations were examined for identified 
subpopulations to obtain quantitative information about differences between those 
subpopulations. Concentrations from all patients, not only from patients classified into 
one of four 'exposure levels' were used. Population curves were obtained by lowess 
regression (S-Plus, version 3.3) [Venables & Ripley, 1984]) fitted to subpopulations. 
Lowess regression is an iterative robust algorithm that fits weighted locally linear 
regression to the data. The result is a smooth curve through the data that downweights 
outliers [Chambers & Hastie, 1992].
Areas under population plasma concentration-time curves (AUPC) were computed 
and compared for subpopulations. In this case a population curve is a purely empirical
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curve, a smoothed 'average' of the data. Therefore the curve can not be extrapolated 
over the boundaries of the data. This means that the computed area under the curve 
would depend on the time of the first and the last data point used to compute the 
curve. Thus, to be able to compare the areas for subpopulations these areas should be 
computed using the same start and stop time. Area Under the Curve (AUC) is a 
strictly defined parameter in pharmacokinetics, with defined time intervals (0 to 
infinity for a single dose or dosing period for a steady state multiple dosing). Time 
intervals of AUPC would not agree with the traditional definition and would depend 
on the data points for the subpopulations. Therefore, instead of presenting absolute 
values of AUPCs, only a comparison of AUPCs for the subpopulations of interest is 
reported.
Quantification of the differences by comparing AUPCs is a univariate procedure: it 
accounts for one variable at a time. Correlation analysis of the covariates identified by 
the tree models was used to determine the appropriate subpopulations for AUPC 
comparisons.
2.3.5 RESULTS
In total, 2161 plasma concentrations from 462 patients were used in the analysis. 
Figure 11 shows scatter plots of all available samples for each study. Though timing 
and amount of data differed across the studies, the range of concentrations was 
approximately the same for all the studies.
Demographics
In order to combine four studies in one analysis, the study population should be 
similar. The data in Table 20 - Table 24 describe the distributions of all the covariates 
across the studies. Table 20 exhibits the distribution (counts and percentages) of 
categorical demographic covariates. Statistically significant differences (Chi-square 
test) are marked with the asterisk (*) and p-values are shown for those variables.
Table 21 shows the distribution (counts and percentages) of patients on concomitant 
medications or therapeutic subclasses of medications. Thirty seven individual drugs or 
groups were used by 25 or more patients. Of them, 11 were distributed differently
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between the studies (p < 0.05 in 2-tail Fisher's exact test). Only these medications are 
presented.
I 8
II
Figure 11. Plasma Concentration versus time after last dose for four studies.
Table 22 - Table 24 show the distributions of continuous variables: age, % above ideal 
body weight, weight and body surface area across the studies.
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Table 20. Distribution of categorical demographic covariates across the studies.
Covariate/ levels
(p-value)a
# patients (N)
Frequency
N (%)
Study
I
157
II
88
III
116
rv
101
Total
462
Gender:
Males
Females
Caucasian
Other
Obesity
No
Yes
Current smoking:
No
Yes
Alcohol
consumption:
Never
Previous
Current
Amount of alcohol:
Seldom
Sometimes
Daily
        »* *   
Disease state
(0.001):
Mild
Moderate
Severe
119(75.8)
38(24.2)
137(87.3)
20(12.7)
83 (52.9)
74(47.1)
97(61.9)
60(38.2)
22(14)
44(28)
91 (58.0)
26 (28.5)
35(38.5)
30(33.0)
15(9.6)
79(50.3)
63(40.1)
76 (86.4)
12(13.6)
77 (87.5)
11(12.5)
49 (55.7)
39 (44.3)
52(59.1)
36(40.9)
14(15.9)
26 (29.5)
48(54.6)
19(39.6)
21(43.8)
8(16.7)
50(56.8)
24(27.3)
14(15.9)
88 (75.9)
22(19)
106(91.4)
10(8.6)
63 (54.3)
53(45.6)
56(48.3)
60(51.7)
21(18.1)
25(21.5)
70 (60.3)
27(38.6)
17(24.3)
26(37.1)
11(9.5)
52(44.8)
53(45.7)
79 (78.2)
28 (27.7)
91 (90.1)
10(9.9)
52(51.5)
49 (48.5)
56(55.5)
45 (44.5)
NA
19(33.9)
20(35.7)
17(30.4)
39(38.6)
42(41.6)
20(19.8)
362 (78.4)
100(21.6)
411(89.0)
51(11)
247 (53.5)
215(46.5)
261(56.5)
201 (43.5)
80(17.3)
117(25.3)
265 (57.4)
91 (34.3)
93(35.1)
81(30.6)
115(24.9)
197(42.6)
150(32.5)
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Covariate/ levels
(p-value)a
# patients (N)
duration of illness:
6MOtolYR
lYRtoSYRS
SYRStolOYRS
>10YRS
Diabetes:
NO
YES
Myocardial
infarction:
NO
YES
Cerebro-vascular
event**(0.002):
NO
YES
Frequency
N (%)
Study
I
157
19(12.1)
66(42.0 )
45(28.7 )
27(17.2)
115(73.2)
42(26.8)
122(77.7)
35(22.3)
148(94.2)
9(5.73)
II
88
6 (6.8)
42(47.7)
21(23.9)
19(21.6)
72(81.8)
16(18.2)
78(88.6)
10(11.4)
73(82.9)
15(17.05)
III
116
5 (4.3)
60(51.7)
30(25.9)
21(18.1)
87(74.0)
29(25.0)
95(81.9)
21(18.1)
92(79.3)
24(20.69)
IV
101
6 (5.9)
48(47.5)
28(27.7)
19(18.8)
77(76.2)
24(23.8)
80(79.2)
21(20.8)
88(87.1)
13(12.87)
Total
462
36 (7.8)
216(46.8)
124 (26.8)
86 (18.6)
351(75.9)
111(24.0)
375(81.1)
87(18.8)
401(86.8)
61(13.2)
a) indicator of significance: p<0.05; ** p<0.01; *** p< 0.001
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